Should I buy or sell Bolt Biotherapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BOLT shares. View BOLT analyst ratings or view top-rated stocks .

What is Bolt Biotherapeutics' stock price target for 2024?

2 brokerages have issued 1 year price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 503.4% from the stock's current price. View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts .

How have BOLT shares performed in 2024?

Bolt Biotherapeutics' stock was trading at $1.12 at the start of the year. Since then, BOLT shares have increased by 3.6% and is now trading at $1.16. View the best growth stocks for 2024 here .

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BOLT earnings forecast .

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.47). The business earned $2.09 million during the quarter, compared to analyst estimates of $1.97 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 51.18% and a negative net margin of 878.58%.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA) , Ampliphi Biosciences (APHB) , Arbutus Biopharma (ABUS) , Aurora Cannabis (ACBFF) , AcelRx Pharmaceuticals (ACRX) , Aldeyra Therapeutics (ALDX) , Apellis Pharmaceuticals (APLS) , Aquinox Pharmaceuticals (AQXP) .

When did Bolt Biotherapeutics IPO?

Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free BOLT Stock Alerts

$1.12

-0.02 (-1.56%)

(As of 01:55 PM ET)

Compare

Today's Range: $1.12
▼
$1.16
50-Day Range: $1.07
▼
$1.50
52-Week Range: $0.84
▼
$2.03

Volume: 35,791 shs
Average Volume: 120,906 shs
Market Capitalization: $42.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Bolt Biotherapeutics alerts:

Bolt Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 503.4% Upside
$7.00 Price Target
Short Interest: Bearish
8.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.68) to ($1.07) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

Medical Sector

663rd out of 918 stocks

Pharmaceutical Preparations Industry

300th out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Bolt Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.20% of the float of Bolt Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Bolt Biotherapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Bolt Biotherapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Bolt Biotherapeutics does not currently pay a dividend.
Dividend Growth
Bolt Biotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BOLT.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Bolt Biotherapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 3 people have searched for BOLT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.40% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.68) to ($1.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bolt Biotherapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bolt Biotherapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bolt Biotherapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

BOLT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BOLT Stock News Headlines

April 15, 2024 | americanbankingnews.com

Contrasting Blueprint Medicines (NASDAQ:BPMC) & Bolt Biotherapeutics (NASDAQ:BOLT)

March 22, 2024 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

April 19, 2024 | DTI (Ad)

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

March 21, 2024 | globenewswire.com

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 27, 2024 | globenewswire.com

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

January 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for Uproleselan

December 5, 2023 | finance.yahoo.com

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

November 11, 2023 | markets.businessinsider.com

Promising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt Biotherapeutics

April 19, 2024 | DTI (Ad)

Start loving Mondays like this

November 9, 2023 | morningstar.com

Bolt Biotherapeutics Inc Ordinary Shares BOLT

November 9, 2023 | finance.yahoo.com

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

October 23, 2023 | finance.yahoo.com

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

October 17, 2023 | finance.yahoo.com

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

September 28, 2023 | finance.yahoo.com

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

September 5, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Participate in September Investor Conferences

August 3, 2023 | msn.com

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates

June 17, 2023 | finance.yahoo.com

US0977021049.SG - Bolt Biotherapeutics Inc.

May 26, 2023 | markets.businessinsider.com

Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy Recommendation

May 13, 2023 | msn.com

SVB Leerink Upgrades Bolt Biotherapeutics (BOLT)

May 12, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)

May 12, 2023 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

April 26, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

April 11, 2023 | finance.yahoo.com

Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year

March 30, 2023 | finanznachrichten.de

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 14, 2023 | finance.yahoo.com

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

January 21, 2023 | reuters.com

BOLT.O - | Stock Price & Latest News | Reuters

See More Headlines

Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:BOLT
CUSIP: 09769810
CIK: 354655
Web: www.boltbio.com
Phone: 650-665-9295
Fax: N/A
Employees: 100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $8.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +514.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,200,000.00
Net Margins: -878.58%
Pretax Margin: -878.58%
Return on Equity: -51.18%
Return on Assets: -37.81%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 5.17
Quick Ratio: 5.17

Sales & Book Value

Annual Sales: $7.88 million
Price / Sales: 5.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.97 per share
Price / Book: 0.38

Miscellaneous

Outstanding Shares: 38,130,000
Free Float: 27,300,000
Market Cap: $43.47 million
Optionable: Not Optionable
Beta: 0.99

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Randall C. Schatzman Ph.D. (Age 69)
CEO & Director
Comp: $829.32k
Dr. Edgar George Engleman M.D. (Age 78)
Founder & Independent Director
Comp: $38.75k
Mr. William P. Quinn (Age 53)
CFO & Secretary
Comp: $594.56k
Mr. Grant Yonehiro C.F.A. (Age 60)
M.B.A., Chief Business Officer
Comp: $544.71k
Dr. Edith A. Perez M.D. (Age 67)
Chief Medical Officer
Comp: $668.32k
Mr. Wesley Burwell
VP & Head of Human Resources
Dr. Nathan Ihle Ph.D.
Senior Vice President of Pharmaceutical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BOLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BOLT shares.
View BOLT analyst ratings or view top-rated stocks.
What is Bolt Biotherapeutics' stock price target for 2024?: 2 brokerages have issued 1 year price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 503.4% from the stock's current price.
View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts.
How have BOLT shares performed in 2024?: Bolt Biotherapeutics' stock was trading at $1.12 at the start of the year. Since then, BOLT shares have increased by 3.6% and is now trading at $1.16.
View the best growth stocks for 2024 here.
When is Bolt Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BOLT earnings forecast.

How were Bolt Biotherapeutics' earnings last quarter?: Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.47). The business earned $2.09 million during the quarter, compared to analyst estimates of $1.97 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 51.18% and a negative net margin of 878.58%.
What other stocks do shareholders of Bolt Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).
When did Bolt Biotherapeutics IPO?: Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.
How do I buy shares of Bolt Biotherapeutics?: Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BOLT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial